Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges.
UBS cuts Neurocrine Bio. stock target to $154, maintains Buy rating
UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $154 from the previous $176, while continuing to recommend the stock as a Buy. Currently trading at $118.
Why Neurocrine Biosciences Stock Sank Today
Both Guggenheim's Yatin Suneja and Wainwright's Andrew Fein were more modest in their Neurocrine price target cuts, with the former shaving $2 off his target to $163 per share and the latter reducing his by $5 to $185. The two analysts also cited projected Ingrezza 2025 sales in their updates, according to reports.
Guggenheim cuts Neurocrine Bio. stock target to $163
Guggenheim maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowered the price target to $163 from $165. The adjustment follows the company's fourth-quarter sales report, which showed Ingrezza sales slightly below consensus estimates.
Neurocrine stock target cut to $185 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $185 from the previous $190 while maintaining a Buy rating on the stock. This revision follows the company's announcement yesterday that Ingrezza,
Fierce Pharma16h
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...
Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Highlights: Record INGREZZA Growth and ...
Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.
Neurocrine price target lowered to $163 from $165 at Guggenheim
Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...